vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and Protagonist Therapeutics, Inc (PTGX). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $170.6M, roughly 1.1× Protagonist Therapeutics, Inc). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs 0.9%, a 76.3% gap on every dollar of revenue. On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs 23.7%). Protagonist Therapeutics, Inc produced more free cash flow last quarter ($182.8M vs $16.0M).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.
FOLD vs PTGX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $170.6M |
| Net Profit | $1.7M | $131.7M |
| Gross Margin | 85.7% | — |
| Operating Margin | 8.6% | 74.3% |
| Net Margin | 0.9% | 77.2% |
| Revenue YoY | 23.7% | 184.4% |
| Net Profit YoY | -88.5% | 381.7% |
| EPS (diluted) | $0.00 | $2.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.2M | — | ||
| Q3 25 | $169.1M | — | ||
| Q2 25 | $154.7M | — | ||
| Q1 25 | $125.2M | — | ||
| Q4 24 | $149.7M | $170.6M | ||
| Q3 24 | $141.5M | — | ||
| Q2 24 | $126.7M | — | ||
| Q1 24 | $110.4M | $255.0M |
| Q4 25 | $1.7M | — | ||
| Q3 25 | $17.3M | — | ||
| Q2 25 | $-24.4M | — | ||
| Q1 25 | $-21.7M | — | ||
| Q4 24 | $14.7M | $131.7M | ||
| Q3 24 | $-6.7M | — | ||
| Q2 24 | $-15.7M | — | ||
| Q1 24 | $-48.4M | $207.3M |
| Q4 25 | 85.7% | — | ||
| Q3 25 | 88.5% | — | ||
| Q2 25 | 90.2% | — | ||
| Q1 25 | 90.7% | — | ||
| Q4 24 | 90.1% | — | ||
| Q3 24 | 90.6% | — | ||
| Q2 24 | 91.1% | — | ||
| Q1 24 | 87.7% | — |
| Q4 25 | 8.6% | — | ||
| Q3 25 | 20.3% | — | ||
| Q2 25 | -6.1% | — | ||
| Q1 25 | -6.3% | — | ||
| Q4 24 | 10.7% | 74.3% | ||
| Q3 24 | 15.3% | — | ||
| Q2 24 | 11.8% | — | ||
| Q1 24 | -25.1% | 80.9% |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 10.2% | — | ||
| Q2 25 | -15.8% | — | ||
| Q1 25 | -17.3% | — | ||
| Q4 24 | 9.8% | 77.2% | ||
| Q3 24 | -4.8% | — | ||
| Q2 24 | -12.4% | — | ||
| Q1 24 | -43.9% | 81.3% |
| Q4 25 | $0.00 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $-0.08 | — | ||
| Q1 25 | $-0.07 | — | ||
| Q4 24 | $0.05 | $2.01 | ||
| Q3 24 | $-0.02 | — | ||
| Q2 24 | $-0.05 | — | ||
| Q1 24 | $-0.16 | $3.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $418.9M |
| Total DebtLower is stronger | $392.7M | — |
| Stockholders' EquityBook value | $274.2M | $675.3M |
| Total Assets | $949.9M | $744.7M |
| Debt / EquityLower = less leverage | 1.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $293.5M | — | ||
| Q3 25 | $263.8M | — | ||
| Q2 25 | $231.0M | — | ||
| Q1 25 | $250.6M | — | ||
| Q4 24 | $249.9M | $418.9M | ||
| Q3 24 | $249.8M | — | ||
| Q2 24 | $260.1M | — | ||
| Q1 24 | $239.6M | $322.6M |
| Q4 25 | $392.7M | — | ||
| Q3 25 | $392.0M | — | ||
| Q2 25 | $391.3M | — | ||
| Q1 25 | $390.7M | — | ||
| Q4 24 | $390.1M | — | ||
| Q3 24 | $389.5M | — | ||
| Q2 24 | $388.9M | — | ||
| Q1 24 | $388.4M | — |
| Q4 25 | $274.2M | — | ||
| Q3 25 | $230.4M | — | ||
| Q2 25 | $204.3M | — | ||
| Q1 25 | $193.6M | — | ||
| Q4 24 | $194.0M | $675.3M | ||
| Q3 24 | $178.8M | — | ||
| Q2 24 | $132.5M | — | ||
| Q1 24 | $130.7M | $560.4M |
| Q4 25 | $949.9M | — | ||
| Q3 25 | $868.8M | — | ||
| Q2 25 | $815.3M | — | ||
| Q1 25 | $789.8M | — | ||
| Q4 24 | $785.0M | $744.7M | ||
| Q3 24 | $786.6M | — | ||
| Q2 24 | $749.5M | — | ||
| Q1 24 | $721.8M | $629.3M |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.02× | — | ||
| Q4 24 | 2.01× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.93× | — | ||
| Q1 24 | 2.97× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $184.2M |
| Free Cash FlowOCF − Capex | $16.0M | $182.8M |
| FCF MarginFCF / Revenue | 8.6% | 107.1% |
| Capex IntensityCapex / Revenue | 0.2% | 0.8% |
| Cash ConversionOCF / Net Profit | 9.62× | 1.40× |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | $101.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.3M | — | ||
| Q3 25 | $35.7M | — | ||
| Q2 25 | $-26.5M | — | ||
| Q1 25 | $7.8M | — | ||
| Q4 24 | $-3.9M | $184.2M | ||
| Q3 24 | $-23.0M | — | ||
| Q2 24 | $22.7M | — | ||
| Q1 24 | $-29.7M | $-27.4M |
| Q4 25 | $16.0M | — | ||
| Q3 25 | $35.3M | — | ||
| Q2 25 | $-28.9M | — | ||
| Q1 25 | $7.5M | — | ||
| Q4 24 | $-4.2M | $182.8M | ||
| Q3 24 | $-23.3M | — | ||
| Q2 24 | $21.6M | — | ||
| Q1 24 | $-31.5M | $-27.7M |
| Q4 25 | 8.6% | — | ||
| Q3 25 | 20.9% | — | ||
| Q2 25 | -18.7% | — | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | -2.8% | 107.1% | ||
| Q3 24 | -16.5% | — | ||
| Q2 24 | 17.0% | — | ||
| Q1 24 | -28.5% | -10.9% |
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 1.6% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | 0.8% | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 1.6% | 0.1% |
| Q4 25 | 9.62× | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.27× | 1.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
PTGX
Segment breakdown not available.
